載入中
NASDAQHealthcareBiotechnology
最新資料
US$3.45
−US$0.31 · -8.24%
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
收盤時
US$3.45
−US$0.31 · -8.24%
盤後
US$3.55
+US$0.10 · +2.90%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
日內區間
目前US$3.45
52週區間
目前US$3.45
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
60
合理估值
情緒
51
多空交錯
風險
66
高風險
動能
17
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
日內區間
目前US$3.45
52週區間
目前US$3.45
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
